Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

MRK Merck and Co Inc

127,47

-0,79 (-0,62%)

04 Mai 2024 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Merck Charts.

Merck (NYSE:MRK)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Merck Charts.

News Merck and Co Inc

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Mittwoch 1 Mai 2024 (5 Tage vor) • Business Wire

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Montag 29 April 2024 (7 Tage vor) • Business Wire

U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower
Donnerstag 25 April 2024 (1 Woche vor) • IH Market News

Futures Pointing To Sharply Lower Open On Wall Street
Donnerstag 25 April 2024 (2 Wochen vor) • IH Market News

Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings
Donnerstag 25 April 2024 (2 Wochen vor) • IH Market News

Merck Announces First-Quarter 2024 Financial Results
Donnerstag 25 April 2024 (2 Wochen vor) • Business Wire

Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) H
Freitag 19 April 2024 (2 Wochen vor) • PR Newswire (Canada)

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Mittwoch 10 April 2024 (4 Wochen vor) • IH Market News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Donnerstag 4 April 2024 (1 Monat vor) • Business Wire

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Mittwoch 3 April 2024 (1 Monat vor) • Business Wire

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Montag 1 April 2024 (1 Monat vor) • Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Donnerstag 28 März 2024 (1 Monat vor) • Business Wire

Weitere Merck and Co Inc News-Artikel

Euro vs Sterling

Deutsche Telekom

JP Morgan Chase

Deutsche Lufthansa

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen